Latest Prednisone Stories
- New Progression-Free Survival Data To Be Presented at 2009 ASCO Annual Meeting Support Further Clinical Development of Picoplatin in Combination with Docetaxel/Prednisone as First-Line Therapy for Metastatic Castration-Resistant Prostate Cancer - - Poniard Management Team to Host Analyst and Investor Briefing to Discuss Data on Sunday, May 31st - SOUTH SAN FRANCISCO, Calif., May 28 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc.
McMaster University researchers have found patients with a very severe asthma benefit from injections of the antibody, mepolizumab.
- New Progression-Free Survival Data Support Picoplatin in Combination with Docetaxel/Prednisone as First-Line Therapy for Metastatic Castration-Resistant Prostate Cancer - - Results To Be Presented at the American Society of Clinical Oncology's 2009 Genitourinary Cancers Symposium - SOUTH SAN FRANCISCO, Calif., Feb.
SAN FRANCISCO, Dec.
Poniard Pharmaceuticals, a biopharmaceutical company focused on oncology, has announced positive incremental data from its ongoing Phase II clinical trial of picoplatin in combination with docetaxel and prednisone as first-line therapy for metastatic hormone-refractory prostate cancer.
U.S. researchers say the use of modern immunosuppressive drugs eliminates the need for steroid therapy as early as seven days following a kidney transplant. Dr.
Cell Genesys, Inc. (Nasdaq:CEGE) today announced its decision to terminate the VITAL-1 Phase 3 clinical trial of GVAX immunotherapy in patients with asymptomatic metastatic hormone-refractory prostate cancer.
DEAR DR. DONOHUE: I am a 78-year-old male who recently experienced a breaking out on my face and around my nose. Pimples came up. My physician diagnosed it as rosacea. He prescribed tetracycline and MetroGel ointment. The area cleared up. I wonder if I can stop taking the prescriptions.
CAMBRIDGE, Mass., Aug. 27 /PRNewswire/ -- Millennium: The Takeda Oncology Company today announced the publication of results from the 682 patient, randomized, Phase III VISTA(1) trial in this week's edition of the New England Journal of Medicine.
Cell Genesys, Inc.
- A volcanic mudflow.